Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1000 CNY

100.0%
Get alerts for future matching vulnerabilitiesLog in to subscribe
I. Basic Information for CVE-2017-9331
Vulnerability Information

Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Description
The Agenda component in Telaxus EPESI 1.8.2 and earlier has a Stored Cross-site Scripting (XSS) vulnerability in modules/Utils/RecordBrowser/RecordBrowserCommon_0.php, which allows remote attackers to inject arbitrary web script or HTML via a crafted meeting description parameter.
Source: NVD (National Vulnerability Database)
CVSS Information
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Type
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Title
Telaxus EPESI Agenda组件跨站脚本漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
Telaxus EPESI是Telaxus公司的一个Web CRM/ERP应用程序,用于存储、组织、访问和共享业务记录,精确的管理各种数据。Agenda component是一个基于Web的用来管理会议信息的组件。 Telaxus EPESI 1.8.2及之前的版本中的Agenda组件的modules/Utils/RecordBrowser/RecordBrowserCommon_0.php文件存在跨站脚本漏洞。远程攻击者可利用该漏洞注入任意的Web脚本或HTML。
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)
Affected Products
VendorProductAffected VersionsCPESubscribe
-n/a n/a -
II. Public POCs for CVE-2017-9331
#POC DescriptionSource LinkShenlong Link
AI-Generated POCPremium

No public POC found.

Login to generate AI POC
III. Intelligence Information for CVE-2017-9331
Please Login to view more intelligence information
IV. Related Vulnerabilities
V. Comments for CVE-2017-9331

No comments yet


Leave a comment